# Spica Therapeutics

Startup profile on Capital Atlas: https://capitalatlas.ai/startups/spica-therapeutics

- Industry: Biotechnology
- Headquarters: Brussels, Belgium
- Website: www.spicatx.com
- Total disclosed funding: $4.4M
- Latest round: Seed (Jun 6, 2025)
- Investors on record: 3

## About

Founded in 2024 and based in Aarhus, Denmark, Spica Therapeutics operates as a biotechnology company that provides therapies for oncology and autoimmune illnesses. The firm was co-founded by Anders Etzerodt (CSO), Jonas H. Graversen (Site Head), Toby Lawrence, Holger J. Møller, and Søren K. Moestrup. In June 2025, Spica Therapeutics raised EUR 10 million in seed funding co-led by new investor Flanders Future Tech and returning investor Bioqube Ventures, with participation from another new investor Qbic Fund. Therapeutics utilizes its proprietary functional macrophage fingerprinting technology to identify and selectively target disease-relevant macrophage subsets. The firm's technology address significant unmet medical needs in therapeutic areas such as oncology, fibroinflammatory, and autoimmune diseases. The company is advancing two lead programs specifically tailored for oncology and fibroinflammatory conditions, utilizing methodologies derived from research at prominent institutions in Europe. The products developed are intended for healthcare providers and researchers engaged in the treatment and study of these complex diseases. The company will use the June 2025 funding for further development of its anti-CD163.

## Funding rounds

- Seed, Jun 6, 2025, $3.3M — PMV, Qbic Fund, Bioqube Ventures
- Seed, Aug 26, 2024, $1.1M — Bioqube Ventures

## Investors

- Bioqube Ventures (https://capitalatlas.ai/funds/bioqube-ventures) — Seed
- PMV (https://capitalatlas.ai/funds/pmv) — Seed
- Qbic Fund (https://capitalatlas.ai/funds/qbic-fund) — Seed